BioSpace News Archive

New preclinical research suggests the ability of BPN14770, an investigational drug under development by Tetra Therapeutics to protect against memory loss and neuronal atrophy induced by amyloid beta1-42, a hallmark protein of Alzheimer’s disease. I

BlackThorn Therapeutics, Inc., a clinical-stage, neurobehavioral health company pioneering next-generation artificial intelligence (AI) technologies to advance targeted therapeutics, today announced the appointment of Monique Levy as chief strategy officer.

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports financial results for the fiscal quarter ended July 31, 2019.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that it has entered into a research agreement with Invectys, a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers

Tilray, Inc. (NASDAQ: TLRY), a global leader in cannabis research, cultivation, production, and distribution, today announced that it has signed a definitive merger agreement with its largest stockholder Privateer Holdings, Inc. (“Privateer”) for a transaction that will extend the lock-up on and provide for the issuance of up to 75 million Tilray shares to Privateer’s equity holders (and the cancellation of the 75 million shares currently owned by Privateer).

Results from the study are expected to be presented in December 2019.

Cementless technology supports growing trend of younger, more active patients undergoing knee replacement [09-September-2019] WARSAW, Ind. , Sept. 9, 2019 /PRNewswire/ -- Johnson & Johnson Medical Devices Companies* announced today that DePuy Synthes** is launching the ATTUNE Cementless Knee in a rotating platform option in select markets around the world. This la

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new patient-reported outcomes data for olorinab, an investigational, oral, peripherally acting, highly-selective, full agonist of the cannabinoid receptor 2 (CB2) in development for the treatment of visceral pain associated with gastrointestinal (GI) disorders, at the European Society of Neurogastroenterology & Motility (ESNM) 2019 NeuroGASTRO Meeting.

The Company will receive a $2 million upfront distribution fee, and future market support for granting the exclusive rights.

Cutera is a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide